The management of postoperative pain after cardiac surgery remains a clinical challenging. Well-controlled pain can help facilitate early recovery and is critical to the physical and psychological well-being of each patient. Opioids are the medications most commonly administered to alleviate postoperative pain, but their use can be associated with challenging side effects.1,2 It was therefore with great interest that I read the recent report by Mamoun and colleagues3 describing their industry-sponsored placebo-controlled clinical trial evaluating the use of intravenous acetaminophen for analgesia during the first 24 hours after cardiac surgery.3 In their single-center study, 147 patients were randomly assigned to receive 1 g of intravenous acetaminophen or placebo every 6 hours for 24 hours starting in the operating room. Mamoun and colleagues3 observed that acetaminophen reduced mean pain scores (on a numeric pain scale that ranged from 0 to 10) by 0.90 (P < .001). It did not, however, reduce postoperative opioid consumption or opioid-related side-effects, such as nausea, vomiting, or respiratory depression.

Before the availability of the study data of Mamoun and colleagues,3 my group recently published a systematic review on the use of intravenous acetaminophen after adult cardiac operations.4 In our review, which summarized 9 articles and data from 586 patients, we noted that when intravenous acetaminophen was added to a background of opioid therapy, minimal clinical benefits were noted—findings similar to those reported by Mamoun and colleagues.3 Moreover, we found that intravenous acetaminophen did not improve postoperative pain scores relative to oral or rectal administration of acetaminophen, irrespective of the higher and more rapid plasma concentrations achieved with intravenous acetaminophen.4

The question remains as to the current role for intravenous acetaminophen after cardiac surgery. In their article, Mamoun and colleagues3 concluded that “intravenous acetaminophen can be an effective analgesic adjunct in patients recovering from median sternotomy.”1 As noted in an accompanying editorial, however, intravenous acetaminophen is quite costly.2 In light of the marginal benefits noted in their trial3 and those reported by others,4 do Mamoun and colleagues believe that the costs justify the routine use of intravenous acetaminophen to all patients after cardiac surgery? Although their results achieved statistical significance, the clinical significance of a 0.90 reduction in pain scores is questionable. I would be pleased to learn whether they administer intravenous acetaminophen to all their cardiac surgical patients at present. Given the results of my group’s systematic review, I believe that intravenous acetaminophen should be used selectively after cardiac surgery.4 In our experience, we limit its administration to select patients who are unable to tolerate oral analgesia during the first 24 to 48 postoperative hours because of severe nausea or ileus. We have also found it be helpful for the management of fever in the initial few hours after surgery and for older patients in whom concerns regarding excessive sedation or confusion limit the use of narcotics and oral analgesics if aspiration remains a risk.

Alexander Kulik, MD, MPH
Lynn Heart and Vascular Institute
Boca Raton Regional Hospital
Charles E. Schmidt College of Medicine
Florida Atlantic University
Boca Raton, Fla

References

http://dx.doi.org/10.1016/j.jtcvs.2016.09.006

INTRAVENOUS ACETAMINOPHEN: CAN THE BENEFIT OUTWEIGH THE COST IN SELECTED PATIENTS?

Reply to the Editor:

Americans view the pharmaceutical industry negatively, surpassed only by their views of the oil and gas industry and the federal government.1 This sentiment is counterintuitive for an industry whose mission is to bring new cures to the public. Poor publicity may in part result from recent substantial and apparently unjustified increases in drug prices. Although the industry argues